| John N Landis Ii, MD | |
|
3300 Main St, 2nd Floor Suite A, Springfield, MA 01107-1112 | |
| (413) 794-7330 | |
| (413) 794-8163 |
| Full Name | John N Landis Ii |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 55 Years |
| Location | 3300 Main St, Springfield, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467547646 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 32516 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baystate Medical Center | Springfield, MA | Hospital |
| Baystate Wing Hospital | Palmer, MA | Hospital |
| Baystate Noble Hospital | Westfield, MA | Hospital |
| Baystate Franklin Medical Center | Greenfield, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Baystate Medical Practices Inc | 5991602971 | 1015 |
News Archive
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, has presented new prospective data demonstrating the strong impact of its 70-Gene Breast Cancer Recurrence assay, MammaPrint, and the corresponding 80-Gene Molecular Subtyping Assay BluePrint, in clinical decision-making for patients with early-stage breast cancer in Germany.
Hospitals and doctors are feeling the health care law heat as officials try to reduce readmissions and increase quality of care in the Medicare program. PBS NewsHour looks at the law's hospital readmissions penalties and Medpage Today explains what the hospitals are doing.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
In studies conducted on the fruit fly, researchers at IRB Barcelona headed by ICREA Professor Marco Milán have revealed that organs have the molecular mechanisms to control their proportions. In this process the protein p53 plays a crucial role. The study is published today in the prestigious journal PLoS Biology.
Similar to patients with Crohn's disease, elderly people with stomach problems have a intestinal barrier that is not functioning optimally.
› Verified 5 days ago
| Entity Name | Baystate Medical Practices Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548205909 PECOS PAC ID: 5991602971 Enrollment ID: O20040225000080 |
News Archive
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, has presented new prospective data demonstrating the strong impact of its 70-Gene Breast Cancer Recurrence assay, MammaPrint, and the corresponding 80-Gene Molecular Subtyping Assay BluePrint, in clinical decision-making for patients with early-stage breast cancer in Germany.
Hospitals and doctors are feeling the health care law heat as officials try to reduce readmissions and increase quality of care in the Medicare program. PBS NewsHour looks at the law's hospital readmissions penalties and Medpage Today explains what the hospitals are doing.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
In studies conducted on the fruit fly, researchers at IRB Barcelona headed by ICREA Professor Marco Milán have revealed that organs have the molecular mechanisms to control their proportions. In this process the protein p53 plays a crucial role. The study is published today in the prestigious journal PLoS Biology.
Similar to patients with Crohn's disease, elderly people with stomach problems have a intestinal barrier that is not functioning optimally.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John N Landis Ii, MD 280 Chestnut St, 2nd Floor, Springfield, MA 01199-1001 Ph: (413) 794-5700 | John N Landis Ii, MD 3300 Main St, 2nd Floor Suite A, Springfield, MA 01107-1112 Ph: (413) 794-7330 |
News Archive
Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, has presented new prospective data demonstrating the strong impact of its 70-Gene Breast Cancer Recurrence assay, MammaPrint, and the corresponding 80-Gene Molecular Subtyping Assay BluePrint, in clinical decision-making for patients with early-stage breast cancer in Germany.
Hospitals and doctors are feeling the health care law heat as officials try to reduce readmissions and increase quality of care in the Medicare program. PBS NewsHour looks at the law's hospital readmissions penalties and Medpage Today explains what the hospitals are doing.
Amgen and Millennium: The Takeda Oncology Company, a subsidiary of Takeda Pharmaceutical Company Limited , today announced that enrollment in the Phase 3 MONET1 trial evaluating motesanib (AMG 706) in combination with paclitaxel and carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) has been temporarily suspended following a planned safety data review of 600 patients by the study's independent Data Monitoring Committee (DMC). Motesanib is part of a broad co-development program between Amgen and Takeda.
In studies conducted on the fruit fly, researchers at IRB Barcelona headed by ICREA Professor Marco Milán have revealed that organs have the molecular mechanisms to control their proportions. In this process the protein p53 plays a crucial role. The study is published today in the prestigious journal PLoS Biology.
Similar to patients with Crohn's disease, elderly people with stomach problems have a intestinal barrier that is not functioning optimally.
› Verified 5 days ago
Grace Makari-judson, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3350 Main Street, Springfield, MA 01107 Phone: 413-794-9338 Fax: 413-794-9754 | |
Peter Whittredge, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 2 Medical Center Dr, Suite 410, Springfield, MA 01107 Phone: 413-781-5735 Fax: 413-732-0225 | |
Dr. Marc A Goldman, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 175 Carew St Ste 200, Springfield, MA 01104 Phone: 413-732-4269 Fax: 413-785-4619 | |
Twara K Tarasaria, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 759 Chestnut St, Springfield, MA 01107 Phone: 413-794-6297 Fax: 413-794-1767 | |
Dr. Joan Wanda Lisak, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 780 Chestnut St, Suite 20, Springfield, MA 01107 Phone: 413-781-2200 Fax: 413-781-2202 | |
Dr. Eva Karacsonyi, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2150 Main Street, Springfield, MA 01104 Phone: 413-739-5676 Fax: 413-739-2278 | |
Dr. Sun Tien Lin, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 125 Liberty St, Suite 204, Springfield, MA 01103 Phone: 413-788-4321 Fax: 413-788-8877 |